Sanofi Pasteur MSD
Sanofi Pasteur MSD is the only European company dedicated exclusively to vaccines and is a leading provider of vaccines in the UK. We were formed in 1994 as a unique joint venture between Sanofi Pasteur, the vaccine division of Sanofi, and Merck, the pharmaceutical company known as MSD outside the US and Canada.
How we work
Unlike other pharmaceutical companies whose business is based upon treating illness, Sanofi Pasteur MSD has only one goal – to prevent disease. Good public health boosts economies, while illness drains them. At a time of global economic challenges, our vaccines can offer Governments a cost-effective way to help keep people healthy and support the long-term success of the UK.
We are dedicated to the highest level of scientific excellence and quality standards in developing, producing, and monitoring our vaccines. We hold ourselves to the highest ethical standards when describing the properties, benefits, and potential risks of our vaccines. The effective use of our vaccines is of utmost importance to us, and our teams work constantly to minimise risk and maximise the benefits of vaccines for people.
How we succeed
The integrity, knowledge, experience, competence, initiative, and commitment of our employees are the key to our success. We work to create an environment of mutual respect and teamwork, where people can do what they love and be rewarded for their performance.
Vaccination today and in the future
Today, many of the serious infections Europeans once feared and suffered from can be prevented – rabies, smallpox, polio and measles to name a few. Sanofi Pasteur MSD vaccines are a key part of this success story. We provide the UK with around 20 effective vaccines, helping to protect against diseases that threaten babies, children, adolescents, adults, and older people.
In the future, scientific research will help us prevent other serious and emerging illnesses.
Sanofi Pasteur MSD has more than 12 investigational vaccines in clinical development. Over the next few years, we intend to introduce the first ever vaccines against dengue fever and Clostridium difficile, the next generation Human papillomavirus (HPV) vaccine, and innovative combination vaccines to help improve infant immunisation.